Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Leases (2019 - 2025)

BioNexus Gene Lab's Operating Leases history spans 7 years, with the latest figure at $116899.0 for Q4 2025.

  • Quarterly results put Operating Leases at $116899.0 for Q4 2025, down 26.82% from a year ago — trailing twelve months through Dec 2025 was $116899.0 (down 26.82% YoY), and the annual figure for FY2025 was $116899.0, down 26.82%.
  • Operating Leases for Q4 2025 was $116899.0 at BioNexus Gene Lab, down from $183746.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $197156.0 in Q2 2025 to a low of $14118.0 in Q3 2022.
  • The 5-year median for Operating Leases is $49842.0 (2021), against an average of $83060.6.
  • The sharpest move saw Operating Leases skyrocketed 642.79% in 2023, then crashed 75.84% in 2024.
  • Year by year, Operating Leases stood at $42909.0 in 2021, then surged by 32.31% to $56775.0 in 2022, then skyrocketed by 134.95% to $133395.0 in 2023, then increased by 19.75% to $159741.0 in 2024, then decreased by 26.82% to $116899.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $116899.0, $183746.0, and $197156.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.